3,6-diazabicyclo[3.1.1]heptaines as neuronal nicotinic acetycholine receptor ligands

Abstract

The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS).

What is claimed is: 
     
         1 . A compound of Formula I: 
       
         
           
           
               
               
           
         
         wherein:
 each m is identical and is 0 or 1; 
 each n is identical and is 0 or 1; 
 when each m is 0, then each n is 1; 
 when each m is 1, then each n is 0; 
 
         R 1  is
 —C(O)—R 3A , 
 —C(O)O—R 3B , 
 
         R 2  is H; 
         R 3A  is methyl, propyl, butyl, pentyl, hexyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, or heterocyclic; 
         R 3B  is methyl, ethyl, propyl, n-butyl, isobutyl, sec-butyl, pentyl, hexyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, or heterocyclic; 
         each R 3A  and R 3B  individually may be optionally substituted with one or more alkyl, alkenyl, alkynyl, aryl, aryloxy, amino, amido, heteroaryl, halogen, hydroxyl, alkoxy, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclic, or alkylamido substituents; 
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         2 . The compound according to  claim 1 , wherein m is 0. 
     
     
         3 . The compound according to  claim 1 , wherein m is 1. 
     
     
         4 . A pharmaceutical composition comprising a compound as claimed in  claim 1 , and a pharmaceutically acceptable carrier.